Related Experiment Video
Updated: Mar 21, 2026

Cardiac Magnetic Resonance for the Evaluation of Suspected Cardiac Thrombus: Conventional and Emerging Techniques
Published on: June 11, 2019
Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera
Éva Pósfai1, Imelda Marton2, Zita Borbényi2
12nd Department of Medicine and Cardiology Centre, Medical Faculty, Albert Szent-Györgyi Clinical Centre, University of Szeged, Szeged-Hungary. evaposfay@gmail.com.
Insights
Myocardial infarction (MI) is a complication of essential thrombocythemia (ET) and polycythemia vera (PV). Early risk factor management is crucial for ET/PV patients to prevent thrombosis.
Area of Science:
- Cardiology
- Hematology
- Oncology
Background:
- Myocardial infarction (MI) is a known complication of essential thrombocythemia (ET) and polycythemia vera (PV).
- Previous analyses of MI in ET/PV patients have been limited to case reports.
Purpose of the Study:
- To evaluate the main cardiological and hematological characteristics of MI in ET/PV patients.
- To improve understanding of myocardial complications in ET/PV.
Main Methods:
- Retrospective analysis of 263 ET/PV patients diagnosed between 1998 and 2014.
- Compared clinical characteristics of 14 MI patients with 162 patients without major thrombotic events.
Main Results:
- 14 MI events (5.3%) occurred in the study cohort.
- Vascular risk factors were present in 92.9% of MI cases.
- 71.4% of MI events occurred within 12 months of ET/PV diagnosis.
Conclusions:
- Early detection and management of vascular risk factors are important in ET/PV patients.
- Further understanding of platelet activation and leukocytes in myeloproliferative neoplasm-related thrombosis could improve prediction and prevention.
Objective:
Detailed analyses of clinical characteristics of myocardial infarction (MI) as an essential thrombocythemia (ET)- and polycythemia vera (PV)-related complication have been so far presented mostly as case reports. Therefore, the aim of this retrospective analysis was to evaluate the main cardiological and hematological characteristics for better understanding myocardial complications in ET/PV.
Methods:
A retrospective analysis was carried out involving 263 patients diagnosed with ET or PV (155/108) between 1998 and 2014. Fourteen patients suffered MI during the hematological follow-up. Their clinical characteristics were compared to 162 patients (97 ET and 65 PV patients) who did not exhibit any major thrombotic complications (MI, stroke/transient ischemic attack, and venous events) before or after hematological diagnosis of ET/PV.
Results:
Fourteen MI events occurred among the 263 patients (5.3%). Vascular risk factors were found in 92.9% (13/14) of analyzed cases. In all, 71.4% of the MI complications developed within 12 months after the diagnosis of ET/PV. The coronary angiography findings revealed ST-elevation MI in four cases and non-ST-elevation MI in 10. Significant stenosis of coronary arteries requiring percutaneous coronary intervention with a stent implantation was present in seven cases, while three had complex stenoses or previous grafts/stents. All of them had undergone coronary artery bypass graft operations.
Conclusion:
The results of the present study suggest that early detection and consideration of individual management of vascular risk factors in ET/PV patients are also important. Furthermore, a better theoretic understanding of platelet activation and role of leukocytes in myeloproliferative neoplasm-related thrombosis could open new perspectives in thrombosis prediction and prevention.
Related Concept Videos
Myocarditis I: Introduction
Myocarditis III: Medical Management
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Myocarditis II: Clinical Features and Diagnostic Tests

